Li Runfeng;Hou Yunlong;Huang Jicheng;Pan Weiqi;Ma Qinhai;Shi Yongxia;Li Chufang;Zhao Jin;Jia Zhenhua;Jiang Haiming;Zheng Kui;Huang Shuxiang;Dai Jun;Li Xiaobo;Hou Xiaotao;Wang Lin;南山 钟;Yang Zifeng
Guangzhou Medical College;Hebei University of Chinese Medicine;Technology Centre;KingMed Virology Diagnostic & Translational Center;China Association for Science and Technology;Macau University of Science and Technology
期 刊：Pharmacological Research
Purpose: Lianhuaqingwen (LH) as traditional Chinese medicine (TCM) formula has been used to treat influenza and exerted broad-spectrum antiviral effects on a series of influenza viruses and immune regulatory effects Ding et al. (2017). The goal of this study is to demonstrate the antiviral activity of LH against the novel SARS-CoV-2 virus and its potential effect in regulating host immune response. Methods: The antiviral activity of LH against SARS-CoV-2 was assessed in Vero E6 cells using CPE and plaque reduction assay. The effect of LH on virion morphology was visualized under transmission electron microscope. Pro-inflammatory cytokine expression levels upon SARS-CoV-2 infection in Huh-7 cells were measured by real-time quantitative PCR assays. Results: LH significantly inhibited SARS-CoV-2 replication in Vero E6 cells and markedly reduced pro-inflammatory cytokines (TNF-α, IL-6, CCL-2/MCP-1 and CXCL-10/IP-10) production at the mRNA levels. Furthermore, LH treatment resulted in abnormal particle morphology of virion in cells. Conclusions: LH significantly inhibits the SARS-COV-2 replication, affects virus morphology and exerts anti-inflammatory activity in vitro. These findings indicate that LH protects against the virus attack, making its use a novel strategy for controlling the COVID-19 disease.